CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MStranslating…

Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve a composite outcome characterized by an absence of […] The post CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS appeared first on Multiple Sclerosis News To